| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | HEPZATO™ (melphalan for Injection/Hepatic Delivery System) Liver-dominant metastatic colorectal cancer (mCRC) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 2 data readout example | HEPZATO™ (melphalan for Injection/Hepatic Delivery System) Liver-dominant metastatic colorectal cancer (mCRC) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 2 data readout example | HEPZATO™ (melphalan for Injection/Hepatic Delivery System) Liver-dominant metastatic colorectal cancer (mCRC) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Delcath Systems, Inc.
$16.75
-0.39 (-2.28%)
C 40Pipeline Score Fair Value Biotech · Clinical
Market Cap
581.20 M
EPS
0.02
P/E Ratio
1,094.77 $
Value Trade
24.03 M
-0.65 %
Week
40.28 %
1 Month
54.66 %
3 Month
68.34 %
6 Month
3.38 %
5 Year
-100 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
417.05 K
52 Week Range
8.12 - 17.42
% held by Insiders
7.58 %
% held by Institutions
50.32 %
Enterprise Value
485.30 M
Total Shares
34.71 M
Short %
7.9 %
Float Shares
27.25 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Delcath Systems, Inc.
832Total events
2Upcoming
183Tier-1 (high impact)
2008 – 2028Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲First Patient DosedHEPZATOFiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-14 | Melphalan/HDS (HEPZATO KIT) | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-09-14 | Melphalan/HDS (HEPZATO KIT) | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-09-14 | Melphalan/HDS (HEPZATO KIT) | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
C40
Pipeline Score $442M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored0.7x
rNPV / MCap Top 63%
Micro Cap (rank 346 of 933)
Percentile RankDelcath Systems, Inc. carries a moderate pipeline score (40/100), with $1.1B risk-adjusted pipeline value, led by Trifluridine-tipiracil plus Bevacizumab Alone in Refractory Metastatic Colorectal Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trifluridine-tipiracil plus Bevacizumab Alone Small molecule | Refractory Metastatic Colorectal Cancer | Phase 2 | NCT06607458 | 10% | $472M | RECRUITING | 90 | AVERAGE | C (50) | Oct 1, 2027 | MODERATE_RISK | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
melphalan | liver-dominant metastatic breast cancer | — | 2026-05-07 | hepatic partial response rate: 60%; median overall survival: 6.0 months; percentage alive at last follow up: 33% Read More | Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 Read More | |
melphalan | liver-dominant metastatic breast cancer | — | 2026-05-07 | hepatic partial response rate: 60%; median overall survival: 6.0 months; percentage alive at last follow up: 33% Read More | Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 Read More | |
melphalan | liver-dominant metastatic breast cancer | — | 2026-05-07 | hepatic partial response rate: 60%; median overall survival: 6.0 months; percentage alive at last follow up: 33% Read More | Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DCTH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DCTH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DCTH▲ +22.5%on this news· ran to +36% by day 3
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Delcath Systems, Inc. reported its financial results for the second quarter of 2026, showing a total revenue of $29.1 million, which is an increase from $24.2 million in the same quarter of 2025. The revenue from the HEPZATO KIT™ also saw a notable rise, reaching $27.1 million compared to $22.5 million in the previous year. This growth highlights the company's ongoing success in the interventional oncology market.
Read more →DCTHDelcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Delcath Systems, Inc. will attend the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA. The company specializes in interventional oncology, particularly for liver cancers. This participation reflects their ongoing commitment to advancing treatment options in this field.
Read more →DCTHDelcath Systems to Host Second Quarter 2026 Earnings Call
Delcath Systems, an interventional oncology company, announced it will host an earnings call on August 6, 2026, to discuss its second quarter results. The call is scheduled for 8:30 AM Eastern Time. This event highlights the company's ongoing commitment to transparency and investor engagement.
Read more →DCTHDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. has announced the granting of equity awards as inducements to four new employees. These awards, approved by the Compensation Committee, are in the form of Restricted Stock Units (RSUs) totaling 17,000 shares. This move is aimed at strengthening the company's workforce as it focuses on treating liver cancers.
Read more →DCTHDelcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems has commenced its Phase 2 clinical trial for HEPZATO, with the first patient dosed at the European Institute of Oncology in Milan. This trial aims to evaluate the drug in combination with standard care for liver-dominant metastatic breast cancer. The study, named DELUMA, represents a significant step in addressing this challenging condition.
Read more →DCTHDelcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Delcath Systems has announced two abstracts related to investigator-initiated trials that will be presented at ASCO 2026. The details of these trials-in-progress are expected to provide insights into ongoing research efforts. This announcement highlights Delcath's commitment to advancing cancer treatment options.
Read more →DCTHDelcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems is set to participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference. This event provides a platform for the company to engage with investors and discuss its business strategies. Further details about the conference and Delcath's agenda were not disclosed.
Read more →DCTHDELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three months ended
Delcath Systems, Inc. reported its first quarter financial results for 2026, showing revenue growth to $25.0 million, primarily driven by strong sales of its HEPZATO KIT product. Despite this positive revenue trend, the company also reported a net loss of $1.1 million and increased research expenses, reflecting ongoing investments in clinical development. Delcath is forecasting total revenue of at least $100 million for the year, buoyed by a projected 20% growth in HEPZATO KIT volumes. The company continues to expand its operational capabilities with a growing number of active treatment centers.
Read more →DCTHDelcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems presented new data on percutaneous hepatic perfusion with melphalan (M-PHP) at the ESMO Breast Cancer Congress 2026. The retrospective analysis involved 15 patients with liver-dominant metastatic breast cancer, showing a 60% hepatic partial response rate. However, safety concerns were noted, with significant adverse events reported. The findings underscore the potential of M-PHP and the need for further studies.
Read more →DCTHDelcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems reported a total revenue of $25.0 million for Q1 2026, marking an increase from $19.8 million in Q1 2025. HEPZATO KIT revenue also saw substantial growth, contributing $23.3 million. However, the company faced a net loss of $1.1 million, a reversal from the previous year's net income. The publication of the CHOPIN trial results is anticipated to positively influence future prescribing patterns.
Read more →DCTHDelcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. will host its first quarter 2026 earnings call on May 7, 2026, at 8:30 AM ET. The call will discuss financial results for the quarter ending March 31, 2026. Delcath is known for its innovative interventional oncology products, including HEPZATO KIT and CHEMOSAT, which target liver cancers.
Read more →DCTHDelcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems, Inc. has announced that its CHEMOSAT Hepatic Delivery System for Melphalan has been included as a recommended liver-directed regional therapy option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma. This recognition may enhance treatment options for patients suffering from this rare form of cancer. The inclusion underscores the system's potential effectiveness and credibility in clinical settings.
Read more →DCTHDelcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Delcath Systems, Inc. will participate in the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto, Canada, from April 11-15, 2026. The company will feature its Hepatic Delivery System in three presentations, highlighting user experiences and preliminary clinical results related to percutaneous hepatic perfusion for liver metastases. This participation underscores Delcath's commitment to advancing treatment options for liver cancer.
Read more →DCTHDelcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath Systems announced the publication of the CHOPIN trial results in The Lancet Oncology, demonstrating the efficacy of combining percutaneous hepatic perfusion with immunotherapy for metastatic uveal melanoma. The trial showed a significant increase in progression-free and overall survival rates. Despite some safety concerns, the results highlight a promising treatment avenue for liver-dominant cancers.
Read more →DCTH▼ -11.9%on this newsshared move
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
Delcath Systems reported strong financial results for Q4 and full year 2025, with total revenue reaching $20.7 million in Q4 and $85.2 million for the year. The company highlighted robust growth in procedure volume and positive operating cash flow, despite increased expenses. Looking ahead, Delcath anticipates continued momentum in 2026 driven by expanded treatment centers and positive clinical data.
Read more →DCTH▼ -11.9%on this newsshared move
DELCATH SYSTEMS, INC. Reconciliation of Reported Net Income (Loss) (GAAP) to Adjusted EBITDA (NON-GAAP Measure) (Unaudited) (in thousands) Three months ended December 31, Twelve months ended
Delcath Systems, Inc. reported its financial results for the fourth quarter and full year 2025, highlighting significant growth in revenues and adjusted EBITDA. The total revenue reached $85.2 million, largely driven by the HEPZATO KIT. Despite a net loss in the fourth quarter, the company has maintained a solid financial position with no debt and over $91 million in cash and investments. Delcath is optimistic about future growth, with projections of at least $100 million in revenue for 2026 and a 20% increase in HEPZATO KIT volume.
Read more →DCTHDelcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
Delcath Systems, Inc. will host a conference call on February 26, 2026, to discuss its fourth quarter and full year results for 2025. The call is set to begin at 8:30 AM Eastern Time. Delcath specializes in interventional oncology, offering products like HEPZATO KIT and CHEMOSAT for liver cancer treatment.
Read more →DCTHDelcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Delcath Systems, Inc. will attend the BTIG 13th Annual MedTech Conference in Utah. The company specializes in interventional oncology, particularly for liver cancers, with products like HEPZATO KIT and CHEMOSAT. HEPZATO KIT is FDA approved for treating metastatic uveal melanoma with specific liver conditions. The conference participation highlights Delcath's ongoing commitment to advancing cancer treatment.
Read more →DCTH▲ +6.2%on this newsshared move
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 21, 2026
Delcath Systems, Inc. has announced the granting of 36,250 Restricted Stock Units (RSUs) to four new employees as part of its 2023 Inducement Plan. These grants are intended to incentivize continued employment and align with Nasdaq Listing Rule 5635(c)(4). Delcath specializes in interventional oncology, particularly for liver cancers, with products like HEPZATO KIT and CHEMOSAT.
Read more →DCTHDelcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results QUEENSBURY, NY
Delcath Systems, Inc. announced preliminary financial results for the fourth quarter and full year 2025, highlighting growth in their interventional oncology approach with HEPZATO. The company's CEO emphasized plans for increased adoption of this treatment through physician awareness of study findings. However, these preliminary results are subject to adjustments and have not been audited yet, raising some uncertainty about their financial reliability before the final report. Delcath aims to utilize its strong financial position to expand its commercial efforts and clinical trials in the upcoming year.
Read more →DCTHDelcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
Delcath Systems has published results from subgroup analyses of the Phase 3 FOCUS study, focusing on the efficacy and safety of the HEPZATO KIT in treating patients with unresectable metastatic uveal melanoma. This publication highlights key efficacy endpoints and safety categories, reinforcing the HEPZATO KIT's position as the only FDA-approved treatment for this condition. The analysis involved 91 patients and provided insights into various prespecified subgroups.
Read more →DCTHDELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three months ended September 30, Nine months ended
Delcath Systems, Inc. reported strong third-quarter financial results for 2025, with total revenue rising to $20.6 million, driven mainly by HEPZATO KIT sales. However, the company experienced a decrease in net income and faced increased expenses in research and commercial activities. Despite these challenges, Delcath maintains a positive outlook for 2025, projecting a significant revenue increase for both HEPZATO and CHEMOSAT, while continuing to validate its clinical programs. The financial report underscored the continued progress of their innovative oncology treatments.
Read more →DCTHDelcath Systems Announces Preliminary Third Quarter 2025 Financial Results
Delcath Systems, Inc. reported preliminary financial results for the third quarter of 2025, including a net income of $0.8 million and a positive operating cash flow of approximately $4.8 million. The company updated its full-year revenue guidance, acknowledging a slight decline in revenue due to NDRA discounts and seasonal impacts. CEO Gerard Michel expressed confidence in achieving significant growth in 2026, supported by the expansion of treatment centers and encouraging results from the CHOPIN trial. An upcoming conference call is scheduled to discuss these developments further.
Read more →DCTHDELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three months ended June 30, Six months ended
Delcath Systems, Inc. reported its financial results for the second quarter of 2025, highlighting a total revenue of $24.2 million, compared to $7.8 million in the same period last year. The company achieved a net income of $2.7 million, reversing a loss of $13.7 million from Q2 2024. HEPZATO KIT sales rose to $22.5 million due to growing utilization and positive feedback from treating physicians. Delcath is expanding access to its products and is optimistic about the future, having activated additional centers and received regulatory approval for its products.
Read more →DCTH▼ -6.3%on this news
Delcath Systems Issues Full Year 2025 Guidance 2025 Full Year Total Revenue Guidance of $94 to $98 million Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement QUEENSBURY, NY
Delcath Systems, Inc. has announced guidance for total revenue in 2025, estimating between $94 to $98 million. Additionally, the company plans to enter a National Medicaid Drug Rebate Agreement to enhance patient access to their therapies. They also anticipate a significant increase in the treatment volume of their HEPZATO kit, with projections of at least 200% growth from the previous year. This strategic move aims to simplify Medicaid access and support the broader adoption of Delcath's innovative cancer treatments.
Read more →DCTHDELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three months ended December 31, Twelve months ended
Delcath Systems, Inc. reported its financial results for the fourth quarter and full year 2024, showcasing a substantial increase in revenues, primarily driven by its HEPZATO product. The company achieved $15.1 million in revenue for the quarter, a significant rise compared to the previous year's figures. Despite a net loss of $3.4 million, Delcath noted positive adjusted EBITDA for the fourth quarter. The company is expanding its operations, with new active treatment centers and a recent FDA clearance for a clinical trial, indicating a positive growth trajectory in its oncology segment.
Read more →DCTH▲ +11.4%on this news
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million QUEENSBURY, NY
Delcath Systems, Inc. has announced preliminary financial results for the fourth quarter and the full year of 2024, reporting approximately $15.1 million in revenue for the fourth quarter and around $37.2 million for the full year. The company is known for its interventional oncology products focused on treating liver cancers, including its HEPZATO KIT and CHEMOSAT systems. A more detailed business update and final financial results are expected to be revealed during the investor call scheduled for March 6, 2025. Investors should note that these results are preliminary and subject to adjustments pending audit processes.
Read more →DCTHDelcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises QUEENSBURY, NY
Delcath Systems, Inc. has announced the exercise of Series E and E1 warrants, resulting in an additional $16.3 million in funding. This capital will support the company's ongoing efforts in the commercialization of its product HEPZATO for treating liver cancers. CEO Gerard Michel highlighted the company's strong financial positioning and plans to invest in new clinical trials to further advance their oncology programs. The warrants were part of a previous private placement and were exercised ahead of their expiration date.
Read more →DCTH▲ +7.6%on this news· ran to +20% by day 3
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results $10 Million Quarterly U.S. Revenue Triggers $25 Million Financing Tranche QUEENSBURY, NY
Delcath Systems announced preliminary revenue results for Q3 2024, reporting $11.2 million total revenue, including $10 million from U.S. sales of HEPZATO KIT. This milestone triggers the exercise of Tranche B warrants from a prior private investment, potentially raising $25 million for the company. The revenue performance reflects the strong demand for HEPZATO KIT and highlights the unmet medical need it addresses in uveal melanoma patients with liver metastases. The company plans to utilize the additional financing to support its commercial launch and expand clinical trials in 2025.
Read more →DCTHDelcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
Delcath Systems, Inc. announced promising results from an independent study published in Therapeutic Advances in Medical Oncology, which focused on liver-directed therapies for patients with liver metastases due to uveal melanoma. The study indicated that these therapies, notably Delcath's CHEMOSAT Hepatic Delivery System, significantly enhance melanoma-specific survival compared to standard systemic therapies. The findings, based on data from patients treated between 2005 and 2021, underscore the importance of these innovative treatments in clinical settings.
Read more →DCTH▲ +13.9%on this news· ran to +34% by day 3shared move
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems, Inc. has announced promising results from an independent study on its CHEMOSAT Hepatic Delivery System for liver tumors. Conducted by researchers at the University Hospital of Leipzig, the study showed significant efficacy and safety in using repeated chemosaturation treatments. Key findings indicate a high rate of disease control among patients, particularly those with limited treatment options or extrahepatic tumor spread. This development underscores the potential of CHEMOSAT as a vital tool in managing both primary and metastatic liver cancers.
Read more →DCTH▼ -5.5%on this news
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath s Board of Directors
Delcath Systems, Inc. announced the appointment of Dr. Bridget Martell to its Board of Directors, effective May 23, 2024. Dr. Martell has a robust background in oncology and biotechnology, having held senior management roles across multiple companies. Her expertise is anticipated to benefit Delcath's mission to improve patient outcomes. Dr. Martell expressed enthusiasm for joining the board at a significant time in the company’s evolution.
Read more →DCTHDELCATH SYSTEMS, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three months ended December 31, Year ended
Delcath Systems, Inc. announced its fourth-quarter and full-year financial results for 2023, highlighting key business developments. The company achieved a pivotal milestone with the first commercial use of the HEPZATO KIT for metastatic uveal melanoma and increased its treatment site activation guidance from 15 to 20 by the end of 2024. While revenue decreased from the previous year, Delcath secured financing and reached important reimbursement milestones, suggesting progress in its business strategy. CEO Gerard Michel emphasized the company's commitment to improving treatment access for patients.
Read more →DCTH▲ +5.3%on this news· ran to +18% by day 3
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath ), an interventional oncology company focused on the treatment of primary and metastatic can
Delcath Systems, Inc. has appointed Martha S. Rook as its new Chief Operating Officer. With over 25 years of experience in various roles related to molecular biology, diagnostics, and biologics manufacturing, Rook's expertise is anticipated to benefit the company as it seeks to expand its production of innovative cancer treatment products, HEPZATO KIT and CHEMOSAT. Rook's previous roles include leadership positions at insitro and Sigilon Therapeutics, where she excelled in technical operations. The appointment includes the grant of stock options as part of her employment agreement.
Read more →DCTH▲ +6.7%on this newsshared move
Delcath Systems Announces $7 Million Private Placement
Delcath Systems, Inc. announced a $7 million private placement through a securities purchase agreement with accredited investors, including existing investors and company executives. The agreement includes the issuance of common stock and pre-funded warrants, with expectations to close by March 19, 2024. The funds raised will be allocated for working capital and other corporate needs. However, the securities involved have not been registered under the Securities Act, which could limit their offer and sale.
Read more →DCTH▲ +7.9%on this news
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO (melphalan/Hepatic Delivery System) Effective
Delcath Systems has received a permanent J-code (J9248) from the Centers for Medicare & Medicaid Services for its HEPZATO (melphalan/Hepatic Delivery System) product, effective April 1, 2024. This coding supports billing for the medication and aims to improve patient access to this specific liver-directed therapy. The HEPZATO KIT is designed for adult patients with metastatic uveal melanoma and may enhance treatment efficiency by minimizing systemic exposure. The company's CEO expressed optimism that this development would significantly aid reimbursement and patient access.
Read more →DCTH▲ +10.3%on this news
Corporate Presentation NASDAQ: DCTH January 2024 Table of Contents Forward-Looking Statement 3 Investment Summary 4 Unmet Need: Liver-Dominant Cancers 5 HEPZATO KIT 8 Metastatic Uveal Melanoma (mUM) 11 FOCUS Trial 16 HEP
Delcath Systems provided a corporate presentation highlighting the HEPZATO KIT, an FDA-approved treatment for metastatic uveal melanoma. The therapy has significant commercial potential with a total addressable market of approximately $600 million. Despite promising prospects, the company faces challenges including supply chain uncertainties and regulatory hurdles. The presentation emphasizes the high unmet medical need for liver-dominant cancers, where current therapeutic options are limited.
Read more →DCTHThe Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to
Delcath's corporate presentation highlights the FDA approval of the HEPZATO KIT, designed for treating liver cancers. It outlines the projected market potential, especially for metastatic ocular melanoma, citing a favorable reimbursement landscape. However, the presentation also emphasizes inherent risks, such as commercialization challenges and dependencies on the supply chain. The company seeks to leverage targeted chemo-delivery to address the significant unmet needs in liver cancer treatments.
Read more →DCTH▲ +81.7%on this news
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma HEPZATO KIT is the only FDA approved liver-directed therapy to
Delcath Systems, Inc. has received FDA approval for HEPZATO KIT, a liver-directed therapy for adult patients with unresectable hepatic-dominant metastatic uveal melanoma. This treatment marks a significant advancement as it is the only approved option for this aggressive cancer type, which has an incidence of approximately 1,000 cases per year in the US. The approval is based on promising results from the FOCUS Study, demonstrating an objective response rate of 36.3%. Commercial availability of HEPZATO KIT is expected in the fourth quarter of 2023.
Read more →DCTH▼ -6.6%on this news
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. has announced the granting of equity awards as inducements for employment to its new Chief Medical Officer and Principal Financial Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include a total of 150,000 shares for Vojislav Vukovic, and 100,000 shares for Sandra Pennell, both issued outside the company's existing equity incentive plan. The inducement grants are structured to vest over a period of time, aligning the interests of the new executives with the long-term performance of the company.
Read more →DCTHDelcath Systems Announces Sandra Pennell as Senior Vice President of Finance
Delcath Systems, Inc. has announced the appointment of Sandra Pennell as the new Senior Vice President of Finance. With over twenty years of experience in various financial roles within the biotechnology sector, she is set to manage the company's financial operations. Ms. Pennell's previous positions include Vice President of Finance at Invivyd, Inc., and Vice President at Vericel Corporation. The appointment is seen as a strategic move as Delcath prepares for the commercialization of its Hepzato Kit, which has a planned FDA date for its application resubmission.
Read more →DCTHDelcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results
Delcath Systems, Inc. reported preliminary financial results and business updates for the first quarter of 2023. The company noted a significant increase in revenue, driven partly by a transition to direct sales in Europe and an increase in product volume. Delcath is preparing to commercialize its Hepzato product, with growing interest from institutions to become treatment centers upon FDA approval, which is expected by August 14, 2023. However, the company cautioned that preliminary financial results may change and that there are inherent risks related to the approval process.
Read more →DCTH▲ +24%on this news
Delcath Systems Announces up to $85 Million Financing Led by Vivo Capital with participation from Logos Capital, BVF Partners, Stonepine Capital Management, LLC, Serrado Capital and supported by existing investor, Rosali
Delcath Systems has announced a financing deal for up to $85 million, led by Vivo Capital with participation from several other investors. The initial $25 million is aimed at supporting the company through the anticipated FDA approval date for its HEPZATO treatment on August 14, 2023. The remaining funds are contingent on meeting specific milestones. Delcath plans to utilize this capital to advance the commercialization of HEPZATO, provided it secures FDA approval.
Read more →DCTH▲ +24%on this newsshared move
Corporate Presentation (NASDAQ: DCTH)
Delcath Technologies is presenting their corporate strategies and updates, highlighting their commitment to develop minimally-invasive cancer treatments, specifically for liver cancers. The company noted progress in their HEPZATO Kit, which has met primary efficacy endpoints in pivotal trials for treating metastatic ocular melanoma. However, they acknowledge several risks tied to regulatory approvals and past safety concerns that could impact their future developments and market entry. The firm is focused on navigating these challenges while aiming for a successful commercial launch.
Read more →DCTHDelcath Systems Announces New Drug Application Resubmission for HEPZATO Kit
Delcath Systems, Inc. has announced the resubmission of its new drug application for the HEPZATO Kit to the FDA. This application seeks approval for treating patients with unresectable hepatic-dominant metastatic ocular melanoma. The submission responds to a previous Complete Response Letter from the FDA and includes extensive data from the FOCUS trial, which indicated a 36.3% overall response rate. However, the FDA's evaluation is pending, which introduces some uncertainty regarding the approval timeline.
Read more →DCTH▲ +15.2%on this news· ran to +28% by day 3
Delcath Systems Announces Private Placement of $6.2 Million
Delcath Systems Announces Private Placement of $6.2 Million NEW YORK, December 8, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a se
Read more →DCTHCorporate Presentation (NASDAQ: DCTH) September 2022 Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its beh
Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties
Read more →DCTHDelcath Systems Closes Private Placement of $5.0 Million
Delcath Systems Closes Private Placement of $5.0 Million NEW YORK, July 20, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously annou
Read more →DCTHCorporate Presentation (NASDAQ: DCTH) June 2022 Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf.
Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties
Read more →DCTHDelcath Systems Reports First Quarter 2022 Results and Provides Business Update NEW YORK Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update NEW YORK Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and fina
Read more →DCTHDelcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upcoming American Society of
Read more →DCTHDelcath Systems to Host First Quarter 2022 Results
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 10, 2022, at 8:30 AM Eastern Time t
Read more →DCTHDelcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate in the Canaccord Genuity Horizons in Oncology Conference: Date: April 1
Read more →DCTHDelcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update NEW YORK Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and met
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update NEW YORK Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business high
Read more →DCTHDelcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will be participating in the Lytham Partners Spring 2022 Investor
Read more →DCTHDelcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full-
Read more →DCTHDelcath Systems to Host Fourth Quarter and Full Year 2021 Results
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 25, 2022, at 8:30 AM Eastern Time
Read more →DCTH▲ +12.7%on this newsshared move
Delcath Systems to Present at the 34th Annual Roth Conference
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will present at the 34th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT.
Read more →DCTHDelcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT in Europe
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that on February 28 its CHEMOSAT Hepatic Delivery System received
Read more →DCTHDelcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that effective March 1, 2022, it will resume direct responsibility for sal
Read more →DCTHDelcath Systems to Present at Upcoming Virtual Investor Conferences
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor confer
Read more →DCTHDelcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that the Company has appointed Anthony Dias as its new Vice President of F
Read more →DCTHDelcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: H.C. Wain
Read more →DCTH▼ -6%on this news· ran to -19% by day 1
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at 12-months
Read more →DCTHDelcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Upd
Read more →DCTHDelcath Systems Announces Third Quarter 2021 Results
Delcath Systems Announces Third Quarter 2021 Results NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlight
Read more →DCTHDelcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: Can
Read more →DCTH▲ +6.5%on this newsshared move
Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a comprehensive Investor Update event on Thursday, December
Read more →DCTHDelcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time
Read more →DCTH▼ -7.5%on this news
Delcath Systems Announces Second Quarter 2021 Results
Delcath Systems Announces Second Quarter 2021 Results NEW YORK August 10, 2021 (GLOBE NEWSWIRE) Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlig
Read more →DCTHDelcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportun
Read more →DCTH▲ +10%on this news
Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern
Read more →DCTHDelcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference.
Read more →DCTHDelcath Systems Set to Join Russell Microcap Index
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell inde
Read more →DCTHDelcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at: LD Micro Virtual Investor Conferenc
Read more →DCTHDelcath Systems to Present at Jefferies Virtual Healthcare Conference
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at: Jefferies Virtual Healthcare Confere
Read more →DCTHDelcath Systems, Inc. Announces First Quarter 2021 Results NEW YORK (GLOBE NEWSWIRE) Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of
Delcath Systems, Inc. Announces First Quarter 2021 Results NEW YORK (GLOBE NEWSWIRE) Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financia
Read more →DCTHDelcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on May 11, 2021 at 8:30 AM Eastern Ti
Read more →DCTHDelcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7, 2021 at 8:30am ET NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focu
Read more →DCTHDelcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the United Kingdom’s (UK) National Institute for Health and Care Excellenc
Read more →DCTHDelcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focu
Read more →DCTHDelcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today provided additional information regarding the power calculation for the Phase 3 FOC
Read more →DCTHDelcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold Conference Call Today at 8:00am Eastern Time NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary
Read more →DCTHDelcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern
Read more →DCTHDelcath Systems to Participate at Upcoming Virtual Investor Conferences
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor
Read more →DCTHDelcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021
Read more →DCTHDelcath Systems Announces Completion of Underwritten Public Offering
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares
Read more →DCTHDelcath Systems Announces Pricing of Public Offering of Common Stock New York
Delcath Systems Announces Pricing of Public Offering of Common Stock New York, December 9, 2020 (GLOBE NEWSWIRE) Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announce
Read more →DCTHDelcath Systems Announces Proposed Public Offering of Common Stock New York
Delcath Systems Announces Proposed Public Offering of Common Stock New York, December 8, 2020 (GLOBE NEWSWIRE) Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced
Read more →DCTHDelcath Systems, Inc. Announces Third Quarter 2020 Results
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended Septe
Read more →DCTHDelcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced management will participate in the Oppenheimer Fall MedTech Summit on Thursd
Read more →DCTHDelcath Schedules Conference Call to Report 2020 Third Quarter Financial Results
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that it will host a conference call on November 11, 2020 at 8:30 AM Eastern
Read more →DCTHDelcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular Melanoma
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that the Company will be hosting a Key Opinion Leader (KOL) call with Dr. Ma
Read more →DCTHDelcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer Gerard Michel Brings the Experience Needed to Lead Delcath as it Transitions from a Development to Commercial Stage Company
Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer NEW YORK, October 1, 2020 (GLOBE NEWSWIRE) Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effect
Read more →DCTHDelcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferenc
Read more →DCTHDelcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ET
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday,
Read more →DCTHLIMITED WAIVER This Limited Waiver, dated
This Limited Waiver, dated July 10, 2020 (this Agreement ), is to provide for a limited waiver of certain provisions of that certain Support and Conversion Agreement dated March 11, 2020, as amended by the Amendment dated April 8 2020 (the Support and Conversion Agreement ), by
Read more →DCTHDelcath Systems, Inc. Announces Second Quarter 2020 Results
Delcath Systems, Inc. Announces Second Quarter 2020 Results NEW YORK, August 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial re
Read more →DCTHDelcath Schedules Conference Call to Report 2020 Second Quarter Financial Results
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that it will host a conference call on August 13, 2020 at 4:30 PM Easte
Read more →DCTHDelcath to Present at Canaccord Genuity 40th Annual Growth Conference
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting
Read more →DCTHDelcath Announces Leadership Transition
Appoints John Purpura as interim Chief Executive Officer. Reiterates intention to announce top-line data from Phase 3 FOCUS trial by year-end Accelerates shift to commercialization planning NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an int
Read more →DCTHDelcath Announces First Quarter 2020 Results
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncolo
Read more →DCTHDelcath Systems Closes $22.0 Million Public Offering of Common Stock
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced underwritten public offering o
Read more →DCTHDelcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a $22 million underwritten public offering o
Read more →DCTHDelcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors
NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board member with experience in pharm
Read more →DCTHsystem for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets; actions by the FDA or other foreign regulatory agencies; the Company's abili
Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastat
Read more →DCTHDelcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced it has completed patient enrollment in its FOCUS registration trial int
Read more →DCTHDelcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on
Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Compa
Read more →DCTHDelcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company’s Board of Directors has authorized a 1-for-700 reverse stock split of
Read more →DCTHDelcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019
NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that Dr. Jennifer Simpson, Ph.D., Chief Executive Officer and Ms. Barbra Keck, Chie
Read more →DCTHDelcath Systems Announces Postponement of Reverse Stock Split
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subseq
Read more →DCTHDelcath Systems Announces Ratio for Reverse Stock Split
Delcath Systems Announces Ratio for Reverse Stock Split NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company s Board of Direc
Read more →DCTHDelcath Systems to Present at the MicroCap Rodeo Investor Conference
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will present at the MicroCap Rodeo. The conference will be held October 15-16, 2019 in Austin, Texas. Management will be available during the day on Octo
Read more →DCTHDelcath Systems to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will participate at the following upcoming investor conferences in New York: Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 20
Read more →DCTHDelcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright
NEW YORK, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH) will present at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright, at 5:05pm on Tuesday, September 10, 2019. The
Read more →DCTHDelcath Systems Closes $9.5 Million Private Placement Bringing total financial amount raised since July 2019 to $29.5M Cash runway past top-line results in 1H2020 with NDA submission anticipated by end of 2020 Recapitali
Delcath Systems Closes $9.5 Million Private Placement Bringing total financial amount raised since July 2019 to $29.5M Cash runway past top-line results in 1H2020 with NDA submission anticipated by end of 2020 Recapitalization provides possible path to NASDAQ listing NEW YORK
Read more →DCTHDelcath Systems Announces $9.5 Million Private Placement
Delcath Systems Announces $9.5 Million Private Placement NEW YORK, NY, August 15, 2019 Delcath Systems, Inc. ( Delcath, the Company , we , our or us (OTCQB: DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $9.5 million at
Read more →DCTHDELCATH ENHANCES BOARD OF DIRECTORS WITH APPOINTMENT OF COMMERCIAL LEADER, JOHN R. SYLVESTER Seasoned leader with successful track record joins to help Delcath in the next phase of its development. NEW YORK (
DELCATH ENHANCES BOARD OF DIRECTORS WITH APPOINTMENT OF COMMERCIAL LEADER, JOHN R. SYLVESTER Seasoned leader with successful track record joins to help Delcath in the next phase of its development. NEW YORK (July 29, 2019) - Delcath Systems, Inc. (OTC Pink: DCTH), an interventi
Read more →DCTHDelcath Systems Closes $20 Million Private Placement
Delcath Systems Closes $20 Million Private Placement NEW YORK, NY, July 17, 2019 Delcath Systems, Inc. ( Delcath, the Company , we , our or us (OTCPK: DCTH) has closed on its previously announced private placement with gross proceeds of $20 million at a combined price of $1,000
Read more →DCTHDelcath Systems Announces $20 Million Private Placement
Delcath Systems Announces $20 Million Private Placement NEW YORK, NY, July 11, 2019 Delcath Systems, Inc. ( Delcath, the Company , we , our or us (OTCPK: DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a c
Read more →DCTHDelcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®—a
Read more →DCTHDelcath Announces Health Authority Approval for CHEMOSAT in Brazil
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has received medical device approval for the CHEMOSAT® Hepatic D
Read more →DCTHForward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements abou
Delcath Investor Presentation (OTCQB: DCTH) February 2019 Exhibit 99.1 Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include s
Read more →DCTHDelcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the
Read more →DCTHDelcath Announces Commercial Licensing Agreement for CHEMOSAT
7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional onc
Read more →DCTHDelcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Registration tria
Read more →DCTHDelcath Announces Third Quarter Fiscal 2018 Financial Results
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended September 30, 2018. Highlights from the third q
Read more →DCTHConsolidated Financial Statements Report of Grant Thornton LLP Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets at
Table of Contents Consolidated Financial Statements Report of Grant Thornton LLP Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets at December 31, 2017 and 2016 F-3 Consolidated Statements of Operations and Comprehensive Loss for the years ende
Read more →DCTHDelcath Announces Enrollment of First Patient in ALIGN Trial
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventio
Read more →DCTHDelcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amen
Read more →DCTHDelcath Raises $8.1 Million from Shareholders in Rights Offering New York, NY, (
Delcath Raises $8.1 Million from Shareholders in Rights Offering New York, NY, (September 27, 2018) Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces the closing of the subsc
Read more →DCTHDelcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription righ
Read more →DCTHDelcath Announces Extension of Rights Offering Period to September 26, 2018
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has completed the initial rights offering period and will be extending for an ad
Read more →DCTHDelcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a study conducted in Germany of the use of the Delcath Hepatic C
Read more →DCTHDelcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 clinical
Read more →DCTHDelcath Announces Pending Expiration to Rights Offering Subscription Period
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the initial expiration, on Monday August 27, 2018, of the subscription
Read more →DCTHDelcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that patient enrollment has begun under the amended protocol for its registration
Read more →DCTHDelcath Issues Letter to Stockholders
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and C
Read more →DCTHDelcath Announces Second Quarter Fiscal 2018 Financial Results
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June 30, 2018. Highlights from the second quart
Read more →DCTHDelcath Announces Commencement of Rights Offering Subscription Period
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday,
Read more →DCTHDelcath Amends Phase 3 Ocular Melanoma Trial Protocol
Revision to Nonrandomized (Single Arm) Study Reduces Trial Size Enrollment Requirement Enrollment Anticipated to be Completed by First Half 2019 NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the tr
Read more →DCTHDelcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights of
Read more →DCTHDelcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led
Read more →DCTHDelcath Systems to Present at the 8th Annual LD Micro Invitational
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June
Read more →DCTHDelcath Sponsors Looking For A Cure Ocular Melanoma Charity Event
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event. A Cu
Read more →DCTHDelcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath
Read more →DCTHDelcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the
Read more →DCTHDelcath Announces First Quarter 2018 Financial Results
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended March 31, 2018. Highlights from the first quarte
Read more →DCTHDelcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal trial of Melphalan Hydrochloride for Injection
Read more →DCTHDelcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delc
Read more →DCTHDelcath Announces Another DSMB Recommendation for Phase 3 Focus Trial
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical tr
Read more →DCTHDelcath Announces Ratio for Reverse Split Authorization
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’
Read more →DCTHDelcath Announces Shareholder Approval of Consent Solicitation
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that shareholders have approved the provisions of the Company’s Consent Solicitation fil
Read more →DCTHDelcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Dr. Brian Steadman, Interventional Oncologist at the Southampton University Hospita
Read more →DCTHDelcath to Present at Oppenheimer 28th Annual Healthcare Conference
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Del
Read more →DCTHDelcath Announces 2017 Financial Results
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the twelve months ended December 31, 2017. Highlights from the fo
Read more →DCTHDelcath Systems, Inc. Delcath Investor Presentation (OTCQB: DCTH) March 2018 Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to
Delcath Investor Presentation Forward-looking Statements contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expectations, beliefs, plans, objectives
Read more →DCTHDelcath to Present at 30th Annual Roth Conference
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Del
Read more →DCTHDelcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has entered into a commercial supply agreement with Tillomed Laboratories, an EMCURE
Read more →DCTHDelcath Announces 500th Commercial CHEMOSAT Treatment in Europe
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have performed the 500th PHP Therapy® treatment using the compa
Read more →DCTHDelcath Announces Satisfaction of 2016 Convertible Note
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has satisfied all of its obligations under the privately placed senior secured co
Read more →DCTHDelcath Announces Special Protocol Agreement Modification With FDA
NEW YORK, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has concluded a modification agreement with the U.S. Food and Drug Administration
Read more →DCTHDelcath Announces Exit from Convertible Note NEW YORK (
Delcath Announces Exit from Convertible Note NEW YORK (December 29, 2017) Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces on December 28, 2017, it entered into exchange agreement
Read more →DCTHDelcath Announces Exit from Convertible Note
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces on December 28, 2017, it entered into exchange agreements (collectively, “Exchange Agreem
Read more →DCTHDelcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical tr
Read more →DCTHDELCATH ENHANCES BOARD OF DIRECTORS WITH APPOINTMENT OF INDUSTRY VETERAN, DR. SIMON PEDDER Distinguished Scientist And Pharmaceutical Executive Brings More Than 30 Years Of Drug Development Leadership NEW YORK (
DELCATH ENHANCES BOARD OF DIRECTORS WITH APPOINTMENT OF INDUSTRY VETERAN, DR. SIMON PEDDER Distinguished Scientist And Pharmaceutical Executive Brings More Than 30 Years Of Drug Development Leadership NEW YORK (November 20, 2017) Delcath Systems, Inc. (OTCQB: DCTHD), an interve
Read more →DCTHDelcath Announces Third Quarter 2017 Financial Results
NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and nine months ended September 30, 2017. Highlights fr
Read more →DCTHDelcath Issues Letter to Shareholders
NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has i
Read more →DCTHDelcath Announces Accelerated Listing on OTCQB
NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that after conversations with both Nasdaq and OTC Markets, the Company is able to effec
Read more →DCTHDelcath Announces Relisting on OTCQB
NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that its Board of Directors has approved the voluntary delisting from NASDAQ. As a resu
Read more →DCTHDelcath Announces Medical University of Hannover in Germany Celebrates 100th CHEMOSAT Treatment
NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, congratulates the team at the Medical University of Hannover Hospital on their performance of the
Read more →DCTHDelcath Announces Agreement for Extinguishment of Convertible Notes with Majority Holder Agreement Contingent upon Shareholder Vote in Favor of the Proposed Reverse Stock Split Voting Deadline Extended to
Delcath Announces Agreement for Extinguishment of Convertible Notes with Majority Holder Agreement Contingent upon Shareholder Vote in Favor of the Proposed Reverse Stock Split Voting Deadline Extended to September 7, 2017 NEW YORK (August 28, 2017) Delcath Systems, Inc. (NASD
Read more →DCTHDelcath Systems, Inc. Announces Extension of Expiration Date of its Consent Solicitation and Ability to Change Consent Once Voted
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today that the deadline for its current Consent Solicitation (the “Consent Solicitation”), currently set to expire at 5:00 p.m. Eastern Time, on August 28, 2017, has been ext
Read more →DCTHDelcath Announces Second Quarter 2017 Financial Results Company Comments on Consent Proposal; Provides Corporate Update NEW YORK (
Delcath Announces Second Quarter 2017 Financial Results Company Comments on Consent Proposal; Provides Corporate Update NEW YORK (August 8, 2017) Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver c
Read more →DCTHShareholder Voting Instructions As set forth in the Definitive Schedule 14A filed with the SEC on
Shareholder Voting Instructions Definitive Schedule 14A filed with the SEC on July 26, 2017, Delcath is soliciting consent for a proposal to effect a reverse stock split. Solicitation materials for this consent have been mailed to all shareholders of record as of the record dat
Read more →DCTHDelcath Systems, Inc. Announces Adjournment of Annual Meeting Meeting Scheduled to Reconvene on June 16
NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today that its 2017 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. The A
Read more →DCTHDelcath Announces First Quarter 2017 Financial Results
NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2017. Highlights for the first qu
Read more →DCTHDelcath Issues Letter to Stockholders NEW YORK (
Delcath Issues Letter to Stockholders NEW YORK (April 27, 2017) Delcath Systems, Inc. (Nasdaq: DCTH) (the Company ), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, Presid
Read more →DCTHDelcath Announces 2016 Financial Results
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the 12 months ended December 31, 2016. Highlights for the fourth
Read more →DCTHDelcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma
NEW YORK, March 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Dru
Read more →DCTHDelcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017
NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer
Read more →DCTHDELCATH SYSTEMS, INC Forward looking Statements This presentation contains forward looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which in
Thomas Vogl , Frankfurt University Hospital Methods retrospective evaluation of non resectable hepatic metastases from uveal melanoma treated with CHEMOSAT o 14 patients treated 2012 2014; patients received 1 3 treatments o 11 PTS evaluated by RECIST criteria; survival time analy
Read more →DCTHDelcath Prices Underwritten Public Offering of Common Stock and Warrants
Delcath Prices Underwritten Public Offering of Common Stock and Warrants NEW YORK, Sept. 30, 2016 /PRNewswire/ Delcath Systems, Inc. (DCTH) (the Company ), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pri
Read more →DCTHDelcath Issues $35 Million in Senior Convertible Notes to Support Melphalan/HDS Clinical Development and CHEMOSAT European Commercialization Proceeds expected to fund operations through year-end 2017 NEW YORK (
Delcath Issues $35 Million in Senior Convertible Notes to Support Melphalan/HDS Clinical Development and CHEMOSAT European Commercialization Proceeds expected to fund operations through year-end 2017 NEW YORK (June 6, 2016) Delcath Systems, Inc. (NASDAQ: DCTH), a specialty phar
Read more →DCTHDelcath Announces 2015 Fourth Quarter and Full Year Financial Results Quarterly and yearly revenue grow more than 50% compared with 2014 NEW YORK (
Delcath Announces 2015 Fourth Quarter and Full Year Financial Results Quarterly and yearly revenue grow more than 50% compared with 2014 NEW YORK (March 21, 2016) Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology wit
Read more →DCTHFIRST AMENDMENT TO THE SERIES B WARRANT OF DELCATH SYSTEMS, INC. This First Amendment to the Series B Warrant of Delcath Systems, Inc. (this Amendment ) is made and effective as of November , 2015 (the Amendment Effectiv
FIRST AMENDMENT TO THE SERIES B WARRANT OF DELCATH SYSTEMS, INC. This First Amendment to the Series B Warrant of Delcath Systems, Inc. (this Amendment ) is made and effective as of November , 2015 (the Amendment Effective Date ) by and among Delcath Systems, Inc., a Delaware c
Read more →DCTHDELCATH SYSTEMS APPOINTS CEO JENNIFER SIMPSON TO BOARD OF DIRECTORS NEW YORK (
DELCATH SYSTEMS APPOINTS CEO JENNIFER SIMPSON TO BOARD OF DIRECTORS (October 6, 2015) Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, annou
Read more →DCTHUNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE DELCATH SYSTEMS, INC 13 Civ. 3494 (LGS) DERIVATIVE SHAREHOLDER LITIGATION 13 Civ. 4002 (LGS) NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION, HEARING TH
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE DELCATH SYSTEMS, INC 13 Civ. 3494 (LGS) DERIVATIVE SHAREHOLDER LITIGATION 13 Civ. 4002 (LGS) NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION, HEARING THEREON, AND RIGHT TO APPEAR Notice is hereby provided
Read more →DCTHDELCATH NAMES DR. JENNIFER SIMPSON PRESIDENT AND CEO NEW YORK (MAY 26, 2015) Delcath Systems, Inc. (NASDAQ: DCTH) announces that Jennifer Simpson, Ph.D., M.S.N., C.R.N.P. has been named President and Chief Executive Offi
DELCATH NAMES DR. JENNIFER SIMPSON PRESIDENT AND CEO NEW YORK (MAY 26, 2015) Delcath Systems, Inc. (NASDAQ: DCTH) announces that Jennifer Simpson, Ph.D., M.S.N., C.R.N.P. has been named President and Chief Executive Officer by the Company s Board of Directors, effective immedia
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) April 2015 Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future fin
Investor Presentation Forward-looking Statements contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expectations, beliefs, plans, objectives, intent
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) March 2015 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to futur
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expec
Read more →DCTHDELCATH REPORTS 2014 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS NEW YORK (
DELCATH REPORTS 2014 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS NEW YORK (March 10, 2015) Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancer
Read more →DCTHDelcath Prices $2.8 Million Public Offering of Common Stock and Warrants
Delcath Prices $2.8 Million Public Offering of Common Stock and Warrants NEW YORK, Feb. 11, 2015 Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it has priced an underwritten public offering of 2,460,000 shares of its common stock and warrants to purchase up to 1,107,
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) January 2015 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to fut
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expec
Read more →DCTHDELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS Industry Veterans Add Clinical Trial, Financial, and Drug Development Expertise New York, NY
DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS Industry Veterans Add Clinical Trial, Financial, and Drug Development Expertise New York, NY December 15, 2014 Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Dr. Dennis H. Langer, William D.
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) November 2014 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to fu
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expec
Read more →DCTHDELCATH REPORTS 2014 THIRD QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY
DELCATH REPORTS 2014 THIRD QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY - November 5, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results for the fiscal third quarter ended September 30, 2014. Developments for the q
Read more →DCTHTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q3 2014 Delcath Systems Inc Earnings Call EVENT DATE/TIME: NOVEMBER 05, 2014 / 09:30PM GMT 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2014 Tho
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q3 2014 Delcath Systems Inc Earnings Call EVENT DATE/TIME: NOVEMBER 05, 2014 / 09:30PM GMT CORPORATE PARTICIPANTS Michael Polyviou Delcath Systems Inc - IR Jennifer Simpson Delcath Systems Inc - Interim President, CEO Barb
Read more →DCTHJennifer Simpson, PH. D. Appointed Interim President and Interim-CEO of Delcath Systems; Roger G. Stoll, PH.D Named Executive Chairman - Company Enhances Clinical Development Program - New York, NY
Jennifer Simpson, PH. D. Appointed Interim President and Interim-CEO of Delcath Systems; Roger G. Stoll, PH.D Named Executive Chairman - Company Enhances Clinical Development Program - New York, NY- September 15, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced the
Read more →DCTHDELCATH REPORTS 2014 SECOND QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY
DELCATH REPORTS 2014 SECOND QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY - August 6, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal second quarter ended June 30, 2014
Read more →DCTHDELCATH REPORTS 2014 FIRST QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY
DELCATH REPORTS 2014 FIRST QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY - May 7, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and corporate developments for the fiscal first quarter ended March 31, 2014. High
Read more →DCTHTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q4 2013 Delcath Systems, Inc Earnings Conference Call EVENT DATE/TIME: MARCH 12, 2014 / 08:30PM GMT 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q4 2013 Delcath Systems, Inc Earnings Conference Call EVENT DATE/TIME: MARCH 12, 2014 / 08:30PM GMT CORPORATE PARTICIPANTS Patty Eisenhaur EVC Group - IR Contact Jennifer Simpson Delcath Systems, Inc. - Interim Co-President
Read more →DCTHDELCATH REPORTS 2013 FOURTH QUARTER AND FULL YEAR RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY
DELCATH REPORTS 2013 FOURTH QUARTER AND FULL YEAR RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY - March 12, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal fourth quarter and f
Read more →DCTHINVESTOR PRESENTATION ex99_1.htm Investor Presentation (NASDAQ: DCTH) January 2014 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federa
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities laws, related to future events and future financial performance which include statements about our expec
Read more →DCTHEXECUTIVE SECURITY AGREEMENT Parties: Delcath Systems, Inc. ( Company ) 810 Seventh Avenue, 35 th Floor New York, New York 10019 ( Executive ) Date: , 2013 ( Effective Date ) RECITALS: 1. Executive is employed by the Com
EXECUTIVE SECURITY AGREEMENT Parties: Delcath Systems, Inc. ( Company ) 810 Seventh Avenue, 35 th Floor New York, New York 10019 ( Executive ) Date: , 2013 ( Effective Date ) Executive is employed by the Company, currently serves as [FULL POSITION TITLE] of the C
Read more →DCTHCONFERENCE CALL TRANSCRIPT ex99_1.htm THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q3 2013 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: NOVEMBER 06, 2013 / 09:30PM GMT 1 THOMSON REUTERS STREET
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q3 2013 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: NOVEMBER 06, 2013 / 09:30PM GMT CORPORATE PARTICIPANTS Doug Sherk EVC Group - IR Jennifer Simpson Delcath Systems, Inc. - Interim Co-President and Co-C
Read more →DCTHDELCATH REPORTS 2013 THIRD QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY
DELCATH REPORTS 2013 THIRD QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - New York, NY - November 6, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal third quarter and nine months end
Read more →DCTHDELCATH TO RAISE APPROXIMATELY $7.5 MILLION New York, NY
DELCATH TO RAISE APPROXIMATELY $7.5 MILLION York, NY -October 23, 2013 Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it is raising approximately $7.5 million in gross proceeds in an offering of 20,960,000 shares of its common stock and warrants to purchase up to 9,4
Read more →DCTHDELCATH SYSTEMS ANNOUNCES STRATEGIC REORGANZATION Company Implements Plan to Reduce Operating Costs; Expected Cash Spend for Q32013 Lower than Previous Guidance New York, NY
DELCATH SYSTEMS ANNOUNCES STRATEGIC REORGANZATION Company Implements Plan to Reduce Operating Costs; Expected Cash Spend for Q32013 Lower than Previous Guidance New York, NY October 4, 2013 Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device comp
Read more →DCTHDELCATH SYSTEMS BOARD OF DIRECTORS IMPLEMENTS LEADERSHIP TRANSITION PLAN Jennifer Simpson and Graham Miao Appointed Interim Co-President and Co-Chief Executive Officer; Gabriel Leung Appointed Chairman of the Board of Di
DELCATH SYSTEMS BOARD OF DIRECTORS IMPLEMENTS LEADERSHIP TRANSITION PLAN Jennifer Simpson and Graham Miao Appointed Interim Co-President and Co-Chief Executive Officer; Gabriel Leung Appointed Chairman of the New York, NY September 13, 2013 Delcath Systems, Inc. (NASDAQ: DCTH),
Read more →DCTHDELCATH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR MELBLEZ TM KIT NEW DRUG APPLICATION NEW YORK, NY - September 13 , 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S.
DELCATH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR MELBLEZTM KIT NEW DRUG APPLICATION NEW YORK, NY - September 13, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) receive
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) August, 2013 2 DELCATH SYSTEMS, INC Forward-looking Statements Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Compa
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which ar
Read more →DCTHCONFERENCE CALL TRANSCRIPT ex99-1.htm THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q2 2013 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: AUGUST 06, 2013 / 08:30PM GMT 1 THOMSON REUTERS STREETEV
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q2 2013 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: AUGUST 06, 2013 / 08:30PM GMT CORPORATE PARTICIPANTS Doug Sherk EVC Group - IR Contact Eamonn Hobbs Delcath Systems - President and CEO Graham Miao De
Read more →DCTHOF DELCATH SYSTEMS, INC., DATED AUGUST 6, 2013 ex99_1.htm DELCATH REPORTS 2013 SECOND QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - QUEENSBURY, NY
DELCATH REPORTS 2013 SECOND QUARTER RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - QUEENSBURY, NY - August 6, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational highlights for the fiscal second quarter and six months ende
Read more →DCTHWILLIAM M. APPLING NAMED EXECUTIVE VICE PRESIDENT OF DELCATH SYSTEMS Company Continues to Increase Efficiencies and Reduce Cash Utilization QUEENSBURY, NY
WILLIAM M. APPLING NAMED EXECUTIVE VICE PRESIDENT OF DELCATH SYSTEMS Company Continues to Increase Efficiencies and Reduce Cash Utilization QUEENSBURY, NY June 26, 2013 Delcath Systems, Inc. (NASDAQ: DCTH) today announced that William M. Appling has been promoted to the newly
Read more →DCTHAnnual Shareholder Meeting (NASDAQ: DCTH)
Annual Shareholder Meeting 2 DELCATH SYSTEMS, INC Forward-looking Statements Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, whi
Read more →DCTHDELCATH REPORTS 2013 FIRST QUARTER RESULTS Conference Call and Webcast Today at 4:30 p.m. ET - QUEENSBURY, NY - May 8 , 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational highlig
DELCATH REPORTS 2013 FIRST QUARTER RESULTS Conference Call and Webcast Today at 4:30 p.m. ET - QUEENSBURY, NY - May 8, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational highlights for the fiscal first quarter ended March 31, 2013. High
Read more →DCTHMAY 08, 2013 / 08:30PM GMT, DCTH - Q1 2013 Delcath Systems, Inc. Earnings Conference Call CORPORATE PARTICIPANTS Doug Sherk Delcath Systems Inc. - IR Contact, EVC Group Eamonn Hobbs Delcath Systems Inc. - President & CEO
CORPORATE PARTICIPANTS Doug Sherk Delcath Systems Inc. - IR Contact, EVC Group Eamonn Hobbs Delcath Systems Inc. - President & CEO Graham Miao Delcath Systems Inc. - EVP & CFO CONFERENCE CALL PARTICIPANTS David Nierengarten Wedbush - Analyst Mary Ellen Kay Aegis Capital Cor
Read more →DCTHDELCATH PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING ON MELBLEZ TM KIT Queensbury, NY
DELCATH PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING ON MELBLEZTM KIT Queensbury, NY - May 2, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 with no abste
Read more →DCTHDELCATH SYSTEMS, INC Forward looking Statements Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking statements made by the Company or on its behalf. This presentation contains forw
Korea 54 DELCATH SYSTEMS, INC CHEMOSAT CENTERS Appendix 8 Active CHEMOSAT Centers in Europe Milan, Italy European Institute of Oncology (IEO) Frankfurt, Germany Johann Wolfgang Goethe Universit t (JWG) Villejuif, France Cancer Institute Gustave Roussy (IGR) Amsterdam, The Netherl
Read more →DCTHDELCATH RECEIVES NOTIFICATION OF PDUFA DATE EXTENSION New PDUFA Goal Date is
DELCATH RECEIVES NOTIFICATION OF PDUFA DATE EXTENSION New PDUFA Goal Date is September 13, 2013 ODAC meeting remains May 2, 2013 NEW YORK, NY - April 8, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S. Food and Drug Administration (FDA) has extended th
Read more →DCTHDELCATH EXPANDS PROGRAM TO INCREASE EFFICIENCIES AND REDUCE CASH UTILIZATION Jennifer Simpson, PhD, MSN, CRNP Named Executive Vice President, Global Head of Business Operations
DELCATH EXPANDS PROGRAM TO INCREASE EFFICIENCIES AND REDUCE CASH UTILIZATION Jennifer Simpson, PhD, MSN, CRNP Named Executive Vice President, Global Head of Business Operations NEW YORK, NY April 8, 2013 Delcath Systems, Inc. (NASDAQ: DCTH) today announced that as a part of th
Read more →DCTHTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q4 2012 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: MARCH 13, 2013 / 08:30PM GMT 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact U
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q4 2012 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: MARCH 13, 2013 / 08:30PM GMT CORPORATE PARTICIPANTS Doug Sherk Delcath Systems Inc - IR Contact, EVC Group Eamonn Hobbs Delcath Systems Inc - President
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) March 2013 2 DELCATH SYSTEMS, INC Forward-looking Statements Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which ar
Read more →DCTHDELCATH REPORTS FOURTH QUARTER AND FULL YEAR 2012 RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - NEW YORK , March 13 , 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and opera
DELCATH REPORTS FOURTH QUARTER AND FULL YEAR 2012 RESULTS - Conference Call and Webcast Today at 4:30 p.m. ET - NEW YORK, March 13, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational highlights for the fiscal fourth quarter and full yea
Read more →DCTHForward looking Statements 2 DELCATH SYSTEMS, INC Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking statements made by the Company or on its behalf. This presentation contains fo
If the Notified Body s assessment is favorable it will issue a Full Quality Assurance Certificate, which enables the manufacturer to draw a Declaration of Conformity and affix the CE mark to the medical devices covered by the assessment o Thereafter, the Notified Body will carry
Read more →DCTHTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Delcath Corporate Update Webinar EVENT DATE/TIME: DECEMBER 05, 2012 / 10:00PM GMT 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2012 Thomson Reut
THOMSON REUTERS STREETEVENTS DCTH - Delcath Corporate Update Webinar DATE/TIME: DECEMBER 05, 2012 / 10:00PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters cont
Read more →DCTHDELCATH SECURES A $35 MILLION COMMITTED EQUITY FINANCING FACILITY WITH TERRAPIN OPPORTUNITY, L.P. Webcast Today at 5:00
DELCATH SECURES A $35 MILLION COMMITTED EQUITY FINANCING FACILITY WITH TERRAPIN OPPORTUNITY, L.P. Webcast Today at 5:00 P.M. ET NEW YORK, December 5, 2012 Delcath Systems, Inc. (NASDAQ: DCTH) announced today that it has obtained a committed equity financing facility (CEFF) un
Read more →DCTHFOR RELEASE AT 4:20PM ET 12/5/12 DELCATH PROVIDES UPDATE ON NDA SUBMISSION FOR ITS CHEMOSATURATION SYSTEM Webcast Today at 5:00
FOR RELEASE AT 4:20PM ET 12/5/12 DELCATH PROVIDES UPDATE ON NDA SUBMISSION FOR ITS CHEMOSATURATION SYSTEM Webcast Today at 5:00 P.M. ET NEW YORK, NY December 5, 2012 Delcath Systems, Inc. (NASDAQ: DCTH) announced today that after recent discussions with the U.S. Food & Drug A
Read more →DCTHTHOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited
NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call CORPORATE PARTICIPANTS Doug Sherk EVC Group, Incorporated - IR Delcath Systems, Incorporated - CEO, President Graham Miao Delcath Systems, Incorporated - EVP, CFO CONFERENCE CALL P
Read more →DCTHDELCATH REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS Conference Call and Webcast Today at 4:30 p.m.
DELCATH REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, November 7, 2012 Delcath Systems (NASDAQ: DCTH) today announced financial results for its third quarter 2012 ended September 30, 2012
Read more →DCTHDELCATH ANNOUNCES JUNE 15, 2013
DELCATH ANNOUNCES JUNE 15, 2013 PDUFA GOAL DATE FOR NEW DRUG APPLICATION NEW YORK, November 1, 2012 Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 15, 201
Read more →DCTHDELCATH SYSTEMS, INC Forward looking Statements This presentation contains forward looking statements within the meaning of the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995. These s
Chir Gastroenterol 2003;19:370 376. 2) Curley SA et al. Ann Surg Oncol 1994;1:389 99. 3) Ravikumar TS et al. J Clin Oncol 1994;12:2723 36. 4) Hwu WJ et al. Oncol Res 1999;11:529 37. No. of pts No. of PHP/ pt Disease stage (tumor diameter) Treatment Median survival (mo) Response R
Read more →DCTHDELCATH REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS Conference Call and Webcast Today at 8:30 a.m.
DELCATH REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS Conference Call and Webcast Today at 8:30 a.m. ET 2012 Delcath Systems (NASDAQ: DCTH) today announced financial results and highlights for its second quarter 2012 ended June 30, 2012 an
Read more →DCTHDELCATH SYSTEMS, INC. SECOND QUARTER 2012
DELCATH SYSTEMS, INC. SECOND QUARTER 2012 CORPORATE UPDATE CALL August 7, 2012, 8:30 ET Operator: Good day, ladies and gentlemen; thank you for standing by. Welcome to the Delcath Second Quarter 2012 Corporate Update Conference Call. During today s presentation, all parties w
Read more →DCTHDELCATH ANNOUNCED CHANGES TO BOARD OF DIRECTORS Pharma Industry Veterans Laura A. Brege and Tasos G. Konidaris Join Delcath Board; Robert Ladd to Retire New York, NY
DELCATH ANNOUNCED CHANGES TO BOARD OF DIRECTORS Pharma Industry Veterans Laura A. Brege and Tasos G. Konidaris Join Delcath Board; Robert Ladd to Retire New York, NY July 9, 2012 Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused
Read more →DCTHDelcath Announces Exercise of Underwriters Over-Allotment option and Closing of $23 million Public Offering of Common Stock and Warrants New York
Delcath Announces Exercise of Underwriters Over-Allotment option and Closing of $23 million Public Offering of Common Stock and Warrants New York, May 31, 2012 Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it has closed the previously announced underwritten public o
Read more →DCTHFINAL TRANSCRIPT DCTH - Q1 2012 Delcath Systems, Inc. Earnings Conference Call MAY 08, 2012 / 4:30PM ET COMPANY PARTICIPANTS Doug Sherk Delcath Systems, Inc. - IR Contact -- EVC Group Eamonn Hobbs Delcath Systems, Inc. -
DCTH - Q1 2012 Delcath Systems, Inc. Earnings Conference Call MAY 08, 2012 / 4:30PM ET COMPANY PARTICIPANTS Doug Sherk Delcath Systems, Inc. - IR Contact -- EVC Group Eamonn Hobbs Delcath Systems, Inc. - President, CEO Graham Miao Delcath Systems, Inc. - EVP, CFO David McDo
Read more →DCTHDELCATH HIGHLIGHTS FIRST QUARTER 2012 AND RECENT ACCOMPLISHMENTS --Conference Call and Webcast Today at 4:30 p.m. ET
DELCATH HIGHLIGHTS FIRST QUARTER 2012 AND RECENT ACCOMPLISHMENTS --Conference Call and Webcast Today at 4:30 p.m. ET-- NEW YORK, May 8, 2012 - Delcath Systems (NASDAQ: DCTH) today announced financial results and highlights for its first quarter 2012 ended March 31, 2012 and rec
Read more →DCTHDELCATH EXPANDS GLOBAL MARKETING TEAM WITH KEY PHARMA ONCOLOGY HIRE Jennifer Simpson Appointed Executive Vice President, Global Marketing
DELCATH EXPANDS GLOBAL MARKETING TEAM WITH KEY PHARMA ONCOLOGY HIRE Jennifer Simpson Appointed Executive Vice President, Global Marketing NEW YORK, NY - March 26, 2012 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Jennifer Simpson, Ph.D., M.S.N., C.R
Read more →DCTHTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q4 2011 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: MARCH 09, 2012 / 03:00PM GMT MARCH 09, 2012 / 03:00PM GMT, DCTH - Q4 2011 Delcath Systems, Inc
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT DCTH - Q4 2011 Delcath Systems, Inc. Earnings Conference Call EVENT DATE/TIME: MARCH 09, 2012 / 03:00PM GMT CORPORATE PARTICIPANTS Bob Jones EVC Group - IR Eamonn Hobbs Delcath Systems, Inc. - President and CEO Graham Miao Delcat
Read more →DCTHDELCATH HIGHLIGHTS FISCAL 2011 FOURTH QUARTER AND FULL YEAR RESULTS AND RECENT DEVELOPMENTS Quarterly Investor Call to be Held Friday
DELCATH HIGHLIGHTS FISCAL 2011 FOURTH QUARTER AND FULL YEAR RESULTS AND RECENT DEVELOPMENTS Quarterly Investor Call to be Held Friday, March 9, 2012 at 10:00AM ET-- NEW YORK, March 8, 2012 - Delcath Systems (NASDAQ: DCTH) today announced highlights of its 2011 fiscal year and
Read more →DCTHDELCATH ANNOUNCES FIRST EUROPEAN CHEMOSAT PROCEDURES Procedures Conducted At European Institute of Oncology Signals Significant Step Forward In Commercialization of the CHEMOSAT Delivery System to Treat Cancers in the Li
DELCATH ANNOUNCES FIRST EUROPEAN CHEMOSAT PROCEDURES Procedures Conducted At European Institute of Oncology Signals Significant Step Forward In Commercialization of the CHEMOSAT Delivery System to Treat Cancers in the Liver NEW YORK, February 2, 2012 - Delcath Systems, Inc. (NA
Read more →DCTHDELCATH SYSTEMS, INC Forward looking Statements This presentation contains forward looking statements, within the meaning of federal securities laws, related to future events and future financial performance which includ
Assume 2.5 treatments per patient 2. Estimated ASP of $25K Sources: LEK Consulting, GLOBOCAN, Company estimates 41 DELCATH SYSTEMS, INC APAC Market by Disease 1. Assume 2.5 treatments per patient 2. Assume ASP of ~$5K China S. Korea (Device) Japan (Device) Taiwan (Device) Austral
Read more →DCTHInvestor Presentation (NASDAQ: DCTH) November 2011 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of federal securities laws, related to future
Investor Presentation 2 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of federal securities laws, related to future events and future financial performance which include statements about our expectat
Read more →DCTHFinal Transcript 1 Final Transcript
CORPORATE PARTICIPANTS Delcath Systems, Inc. - CEO, President, Director Delcath Systems, Inc. - EVP, CFO Delcath Systems, Inc. - EVP, Research and Development, CMO CONFERENCE CALL PARTICIPANTS ROTH Capital Partners - Analyst Canaccord Capital - Analyst Good day, ladies and
Read more →DCTHDELCATH ANNOUNCES FISCAL 2011 THIRD QUARTER RESULTS AND RECENT DEVELOPMENTS -- Quarterly Investor Call to be Held Monday
DELCATH ANNOUNCES FISCAL 2011 THIRD QUARTER RESULTS AND RECENT DEVELOPMENTS -- Quarterly Investor Call to be Held Monday November 7, 2011 at 4:30pm ET -- NEW YORK, November 7, 2011 - Delcath Systems (NASDAQ: DCTH) today reported financial results for the fiscal 2011 third quar
Read more →DCTHFDA SCHEDULES DELCATH PRE-NEW
FDA SCHEDULES DELCATH PRE-NEW DRUG APPLICATION MEETING DATE NEW YORK, October 26, 2011 - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application
Read more →DCTHDELCATH EXPANDS SENIOR MANAGEMENT TEAM Graham G. Miao Appointed Chief Financial Officer; David McDonald Appointed Executive Vice President, Business Development
DELCATH EXPANDS SENIOR MANAGEMENT TEAM Graham G. Miao Appointed Chief Financial Officer; David McDonald Appointed Executive Vice President, Business Development NEW YORK, NY September 26, 2011 Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Graham G. Mi
Read more →DCTHDELCATH ANNOUNCES UPDATED EFFICACY RESULTS FROM PHASE 3 TRIAL OF CHEMOSATURATION FOR MELANOMA METASTASES IN THE LIVER PRESENTED AT EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS March 2011 Data Confirm Strong Treatment Effec
DELCATH ANNOUNCES UPDATED EFFICACY RESULTS FROM PHASE 3 TRIAL OF CHEMOSATURATION FOR MELANOMA METASTASES IN THE LIVER PRESENTED AT EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS March 2011 Data Confirm Strong Treatment Effect of Chemosaturation NEW YORK and STOCKHOLM, SWEDEN, Septe
Read more →DCTHPOSITIVE PHASE 2 TRIAL RESULTS FROM NEUROENDOCRINE TUMOR COHORT PRESENTED AT CIRSE Chemosaturation Demonstrates Clinically Meaningful Tumor Response with Unresectable Neuroendocrine Tumors in the
POSITIVE PHASE 2 TRIAL RESULTS FROM NEUROENDOCRINE TUMOR COHORT PRESENTED AT CIRSE Chemosaturation Demonstrates Clinically Meaningful Tumor Response with Unresectable Neuroendocrine Tumors in the Liver NEW YORK and MUNICH, GERMANY, September 12, 2011 - Delcath Systems, Inc. (
Read more →DCTHDELCATH ANNOUNCES TOP-LINE RESULTS FROM METASTATIC COLORECTAL COHORT IN PHASE II TRIAL OF CHEMOSATURATION SYSTEM Confirms Plans to Initiate New Phase II Single-Arm Study of Patients with Metastat
DELCATH ANNOUNCES TOP-LINE RESULTS FROM METASTATIC COLORECTAL COHORT IN PHASE II TRIAL OF CHEMOSATURATION SYSTEM Confirms Plans to Initiate New Phase II Single-Arm Study of Patients with Metastatic Colorectal Cancer of the Liver in 2012 NEW YORK, NY - September 1, 2011 -- Delca
Read more →DCTHDelcath Systems, Inc. (DCTH) to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, May 13, 2010 (GLOBE NEWSWIRE) -- Eamonn P. Hobbs, Chief Executive Officer, President and Director of Delcath Systems, Inc. (DCTH) will visit NASDAQ MarketSite in Times Square and preside over the NASDAQ Opening Bell. NASDAQ MarketSite -- 4 Times Square -- 43rd & Broad
Read more →DCTHDelcath Systems to Present at the Rodman Renshaw 10th Annual Global Healthcare Conference
NEW YORK, NY--(Marketwire - November 7, 2008) - Delcath Systems (NASDAQ: DCTH), a leading developer of regional therapy for cancer, announced today that their President and CEO, Richard Taney, will present at the Rodman & Renshaw 10th Annual Global Healthcare Conference in New
Read more →DCTHDelcath Systems' President and CEO Richard Taney to Present at Two Medical Technology Conferences
NEW YORK, NY--(Marketwire - October 21, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) a leading developer of regional therapy for liver cancer announced today that President and CEO Richard Taney will participate in a Panel Discussion on "Combination Products: A Convergence of
Read more →DCTHDelcath Systems Appoints Eamonn Hobbs to Board of Directors
NEW YORK, NY--(Marketwire - October 15, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Mr. Eamonn Hobbs to Delcath's Board of Directors. Mr. Hobbs is President and Chief Executive Officer of AngioDynamics, Inc. (NASDAQ: ANGO), a leading medical
Read more →DCTHDelcath Systems to Present at the Maxim Group Growth Conference
NEW YORK, NY--(Marketwire - October 2, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH), a leading developer of regional therapy for cancer, announced today that its management will present at the Maxim Group Growth Conference in New York City on Tuesday, October 7, 2008. The conf
Read more →DCTHDelcath Adds Providence Cancer Center to Phase III Trial
NEW YORK, NY--(Marketwire - September 24, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Robert W. Franz Cancer Research Center, a part of the Providence Cancer Center, located in Portland, Oregon, has joined Delcath's Phase III clinical trial for the tr
Read more →DCTHDelcath Systems Targeted Drug Delivery Technology to Be Presented at Western Angiographic and Interventional Society Annual Meeting
NEW YORK, NY--(Marketwire - September 19, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH), a leading developer of regional therapy for cancer, today announced that Dr. Charles Nutting of Swedish Medical Center in Englewood, Colorado will deliver a presentation at the 38th Annual
Read more →DCTHDelcath Cancer Trials Welcome New Principal Investigator From NCI
NEW YORK, NY--(Marketwire - September 2, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the National Cancer Institute (NCI) has named Dr. Marybeth S. Hughes, MD as the Principal Investigator for the current Phase III and Phase II clinical trials of the Compa
Read more →DCTHDelcath Systems to Host Quarterly Update Conference Call
NEW YORK, NY--(Marketwire - August 28, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company will host a quarterly update conference call. Richard Taney, President and Chief Executive Officer of Delcath Systems, will host the call beginning at 4:30 pm E
Read more →DCTHDelcath Expands Phase III Trial for Metastatic Melanoma to Include Swedish Medical Center in Colorado
NEW YORK, NY--(Marketwire - August 21, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Swedish Medical Center in Englewood, Colorado, has joined Delcath's Phase III clinical trial for the treatment of metastatic melanoma in the liver. Swedish Medical Cent
Read more →DCTHDelcath Expands Phase III Trial for Metastatic Melanoma to Include John Wayne Cancer Institute in California
NEW YORK, NY--(Marketwire - August 12, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the John Wayne Cancer Institute ("JWCI"), at Saint John's Health Center in Santa Monica, California, has joined Delcath's Phase III clinical trial for the treatment of meta
Read more →DCTHDelcath Systems to Present at the 28th Annual Canaccord Adams Global Growth Conference
NEW YORK, NY--(Marketwire - August 7, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that Richard L. Taney, President and CEO of Delcath Systems, Inc., will present at the 28th Annual Canaccord Adams Global Growth Conference on Tuesday, August 12th, 2008 at 10:30
Read more →DCTHDelcath Expands Phase III Trial for Metastatic Melanoma to Florida
NEW YORK, NY--(Marketwire - July 24, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that Moffitt Cancer Center ("Moffitt"), a National Cancer Institute Comprehensive Cancer Center, has joined Delcath's Phase III clinical trial for the treatment of inoperable meta
Read more →DCTHDelcath Systems Announces Clinical and Regulatory Appointments
NEW YORK, NY--(Marketwire - July 17, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today the addition of two senior executives as the Company accelerates its Phase III clinical trial towards completion. Mark Morrison, M.D., Ph.D. joins Delcath as Chief Medical Officer
Read more →DCTHDelcath Systems' Targeted Drug Delivery System for Liver Cancer Treatment to Be Featured on FOX Business News
NEW YORK, NY--(Marketwire - July 15, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that CEO Richard L. Taney will appear on FOX Business Network (FBN) to discuss the Company's proprietary Percutaneous Hepatic Perfusion (PHP) System, which is designed to deliver
Read more →DCTHDelcath Expands Multi-Center Phase III Trial for Metastatic Melanoma
NEW YORK, NY--(Marketwire - June 24, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the University of Texas Medical Branch at Galveston (UTMB), part of the University of Texas System, has joined Delcath's Phase III clinical trial for the treatment of inopera
Read more →DCTHDelcath Announces Expanded Clinical Initiatives at Annual Meeting Today
NEW YORK, NY--(Marketwire - June 4, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) will hold its Annual Meeting of Shareholders today at the Omni Berkshire Hotel in New York City at 11:00 AM EDT. Richard L. Taney, President and Chief Executive Officer of the Company, will be upd
Read more →DCTHDelcath Reports on 2005 Annual Meeting
STAMFORD, Conn., June 15, 2005 (PRIMEZONE) -- Delcath Systems, Inc. (Nasdaq:DCTH) reported shareholders attending the company's 2005 annual meeting voted in favor of the re-election of Samuel Herschkowitz, MD, chairman, and M. S. Koly, chief executive officer, as directors for th
Read more →DCTHDelcath Receives Fast-Track Status from U.S. FDA for High Dose Cancer Treatment with Melphalan
STAMFORD, Conn., May 11, 2005 (PRIMEZONE) -- Delcath Systems, Inc. (Nasdaq:DCTH) said its novel system for delivering high dose chemotherapy to specific organs and body regions received fast-track status from the U.S. FDA for treating metastatic melanoma in the liver with melphal
Read more →Competitive Position
How DCTH ranks across every disease it competes inCompetitive Position is a premium feature
See how DCTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial